Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World - 2How did humans evolve, and will we evolve more?
- 3Strength training is crucial after menopause. How to make the most of your workouts
- 4Figuring out the Business venture Code: The Response to Building an Effective Startup
- 53 Must-Change Settings for iPhone Clients: Safeguard Yourself !
- Former United Launch Alliance CEO Tory Bruno joins competitor Blue Origin for national security projects
- Countdown begins for long-awaited Artemis II moon mission
- Authentic Urban areas: Rich Legacy and Lively Societies
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- Israel launches new wave of attacks against Hezbollah in Beirut
- 7 Fun Plans to Make Film Evenings Seriously Invigorating (You'll Cherish #5!)
- One-third of asylum applications by Iranians approved in Germany
- How to track NASA’s Artemis II and Orion’s journey to the moon
- RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
